GlassScriptPhysician profile
Noelle L Pruzan
NPI 1093031858
$2,281.05
in general payments reported to CMS, 2019-2025
14 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what 76% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.71 · 2020: $28.48 · 2021: $24.66 · 2022: $283 · 2023: $191 · 2024: $44.55 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,312 · Food and Beverage: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,312.45 |
| Food and Beverage | $542.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,701.96 | 2022-2025 | Vyzulta |
| Abbvie INC. | $175.21 | 2022-2023 | |
| Alcon Vision LLC | $63.74 | 2022-2023 | Rocklatan |
| Aerie Pharmaceuticals, INC. | $59.73 | 2019-2021 | |
| Sight Sciences, INC. | $48.84 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $44.55 | 2024 | Tecnis Iol |
| Allergan, INC. | $33.18 | 2020-2022 | |
| Horizon Therapeutics Plc | $33.13 | 2022 | |
| Novartis Pharmaceuticals Corporation | $31.81 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.63 | 2019 | |
| Rayner Intraocular Lenses Limited | $19.35 | 2023 | Omidria, Rayone Aspheric, Rayone Emv |
| Sun Pharmaceutical Industries INC. | $15.67 | 2022 | |
| New World Medical,INC. | $15.61 | 2022 | |
| Optovue, INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noelle Pruzan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.